TuHURA Q1 cash $6.3M; secures $50M credit facility; IFx-2.0 gets ODD in melanoma

TuHURA Biosciences, Inc./NV

Cash and equivalents $6.3M at March 31, 2026; net operating cash outflow $4.4M in Q1.
Established $50M credit facility with largest stockholder at 12% interest, maturing 2031; extends runway into 2028.
R&D expenses $5.2M (up from $4.6M YoY); G&A $2.3M (up from $2.0M YoY).
FDA Orphan Drug Designation granted for IFx-2.0 in stage IIB-IV melanoma.
Appointed Craig Tendler as CMO and Amanda Garofalo as SVP Clinical Operations.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TuHURA Biosciences, Inc./NV reported financial results for three months ended March 31, 2026.

Period: three months ended March 31, 2026
Result: reported results

Exact text from the filing

Summary of Financial Results for the First Quarter 2026 Cash and cash equivalents of $6.3 million at March 31, 2026. TuHURA's total common shares outstanding were approximately 63.6 million. Research and development expenses were $5.2 million and $4.6 million for the 3 months ended March 31, 2026, and 2025, respectively. General and administrative (G&A) expenses were $2.3 million and $2.0 million for the 3 months ended March 31, 2026, and 2025, respectively. Net cash outflows from operating activities were ($4.4) million and ($4.7) million for the 3 months ended March 31, 2026, and 2025, respectively. Net cash flows from financing activities were $ 7.2 million and $ (0.5) million for the 3 months ended March 31, 2026, and 2025, respectively.

View on SEC.gov

10 earnings releases filed in the last 30 days. Browse all earnings releases →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0001193125-26-227204

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.